Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $6
Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $13 to $6.
NextCure Announces Initiation Of Phase 1b/2 Clinical Trial To Evaluate NC410 In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Immune Checkpoint Refractory Or Naïve Solid Tumors
NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
Truist Securities Maintains Buy on NextCure, Lowers Price Target to $15
Truist Securities analyst Asthika Goonewardene maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $19 to $15.
Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $13
Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $21 to $13.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.